Plain-English translation of NCT06944587 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
NORPACT-3 is a Norwegian study that tests a new treatment approach for people with pancreatic cancer that is either borderline resectable or locally advanced. You would receive as your first treatment, and then your doctors would evaluate whether surgery to remove the cancer is possible. The study aims to see how many patients can eventually have surgery and how well they survive with this approach.
Pancreatic cancer is very difficult to treat, especially when it has grown into nearby blood vessels or organs. This trial exists to find out whether starting with to shrink the tumor first makes it more likely that doctors can surgically remove it — and whether this improves how long patients survive.
You likely qualify if…
You likely don't qualify if…
You would first receive according to Norwegian treatment guidelines — this is the main treatment phase. After , your doctors will do imaging scans and tests to see if surgery to remove the cancer is now possible. If surgery is appropriate and safe for you, you may then have an operation to remove the pancreas and any affected tissues. Throughout the study, you'll be monitored for how well the treatment works, your survival, and any side effects, following a structured national protocol across all Norwegian pancreatic surgery centers.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Norway